Table 3 The association between MTHFR polymorphism and clinical outcomes

Goekkurt 2006 [11]

CC: 10/28; CT+TT: 3/22

NR

NR

Ruzzo 2006 [14]

CC: 13/34; CT+TT: 57/141

NR

NR

Lu 2004 [25]

CC: 2/24; CT+TT: 20/51

NR

Nausea/vomiting: P=0.002

Shitara 2010 [27]

NR

TT/(CT+CC): 0.57 (0.33, 0.97)

NSS

Huang 2009 [28]

NR

TT/(CT+CC): 0.595 (0.349, 1.012)

NR

Goekkurt 2009 [31]

CC: 18/59; CT+TT: 34/75

NR

NSS

Ott 2006 [32]

CC: 16/50; CT+TT: 17/85

CT/CC: 1.8 (1.13, 2.88); TT/CC: 0.93 (0.54, 1.62)

NR

Ott 2011 [33]

NR

CT/CC: 0.8 (0.50, 1.36); TT/CC: 0.5 (0.18, 1.49)

NR

Lee 2005 [34]

NR

CT/CC: 0.91 (0.58, 1.43); TT/CC: 1.16 (0.65, 2.08)

NR

Combined analysis (OR/HR, 95CI %)

OR: (CT+TT)/CC

CT/CC (total): 1.10 (0.67, 1.79);

___

Total: 1.12 (0.49, 2.55); RECIST subgroup: 0.28 (0.07, 1.20);

CT/CC (Asian subgroup): 0.91 (0.58, 1.43);

WHO subgroup: 7.1 (1.5, 33.53);

CT/CC (European subgroup): 1.21 (0.54, 2.67);

Others subgroup: 1.05 (0.51, 2.16);

CT/CC (Palliative subgroup): 0.91 (0.58, 1.43);

Asian subgroup: 7.1 (1.5, 33.53);

CT/CC (Neoadjuvant subgroup): 1.21 (0.54, 2.67) TT/CC (total): 0.94 (0.65, 1.37);

European subgroup: 0.85 (0.41, 1.77)

TT/CC (Asian subgroup): 1.16 (0.65, 2.08);

Palliative subgroup: 1.40 (0.55, 3.60);

TT/CC (European subgroup): 0.81 (0.50, 1.33);

Neoadjuvant subgroup: 1.12 (0.49, 2.55)

TT/CC (Palliative subgroup): 1.16 (0.65, 2.08);

TT/CC (Neoadjuvant subgroup): 0.81 (0.50, 1.33)